Chargement...

Robocath in a few words

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes smart robotic solutions to treat cardiovascular diseases. As an active player in the digital evolution of the medical industry, its smart connected solutions aim to enhance hand gestures and make medical procedures safer.

Robocath develops robotic solutions which integrate a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are all compatible with market-leading devices and cathlabs.

The company received the CE marking for R-One, its first robotic solution, in 2019. In a prospective, multicenter, non-randomized, single-arm clinical trial, R-One demonstrated safety and efficacy as it achieved more than 95% technical procedure success with no MACE (major adverse cardiovascular events). Currently R-One is used in Europe, Africa and China.

By pursuing the development of smart digital solutions, Robocath aims to become a world leader in vascular robotics. Based in Rouen, France, Robocath has more than 70 employees.

History

2009
Company foundation
2013
First in vivo tests
2014
ISO 13485 certification granted
2015
Industrial prototype
2017
Safety-Efficacy study
2019
R-One pre-launch and First-In-Man procedures
2021
First remote procedure (120 km)
2022
R-Evolution study conclusion
2023
R-One+ launch

Robocath in the world

19 Rue Marie Curie, Rouen, France

Management

Philippe BENCTEUX

Founder & CEO
Learn more
A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.

Philippe JEANNOT

COO
Learn more
An engineer from the Ecole Centrale Paris, Philippe Jeannot has extensive experience in industry, start-ups and technology SMEs in R&D, Quality and General Management positions. With international experience, he joined Robocath in November 2024 to take the company to a new level of growth and efficiency.

Bruno FOURNIER

CTO
Learn more
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.

François OECHSEL

Supply Chain Director
Learn more
François Oechsel holds a first Master's degree in Biomechanics and a second in Mechanical Engineering. He has 20 years of experience in technical development and procurement. He started his career at Aptar in 1994, where he was a project manager, before holding management positions in purchasing and then packaging in companies such as Boehringer Ingelheim, Delpharm or Johnson & Johnson. He joined Robocath in March 2022.

Learn more

Strategic Committee

Jonathan CHEN

MICROPORT
Learn more
Mr. Jonathan Chen is the Chief International Business Officer of the MicroPort Scientific Corporation, Chairperson of Intercontinental CRM Committee, Co-Chairperson of InterContinental Orthopedics Committee and a member of the General Management Committee of MicroPort. Prior to current positions, he has served as the Executive Vice President of International Operations and Investor Relations of the Company. Mr. Chen's primary responsibilities include growing the company's International business in markets of the U.S, Europe, Asia Pacific and Latin America. Mr. Chen has over 23 years of experience in the medical device industry. Prior to joining the Company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for 6 years, where he was Senior Vice President of Business Development & Financial Strategy. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons.

Pierre-Emmanuel STRUYVEN

SUPERNOVA INVEST
Learn more
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).

Haitong Wang

ZHEJIANG SILK ROAD FUND
Learn more
Mr. Haitong Wang is managing partner at Zhejiang Silk Road Fund. Zhejiang Silk Road Fund is a Chinese private equity fund focusing on cross-border investments across various sectors, including healthcare, advanced manufacturing, TMT, and consumer. The fund is managed by Zhejiang United Investment Group (‘ZUIG’), an investment firm backed by eight Zhejiang-based entrepreneurs. ZUIG currently has about RMB 12 billion ($1.7b) assets under management and has offices in Hangzhou, Shanghai, Hong Kong, and Shenzhen.

Arthur DUWIQUET

Normandie Participations
Learn more
Director of Innovation at Normandie Participations, Arthur is a Venture Capital specialist. He invests in equity and quasi-equity in the early stages of development of innovative start-ups and SMEs in Normandy. An engineer with a Specialized Master's Degree in Industrial Business Engineering from INSA Toulouse, he began his career abroad in the energy sector before joining BPI France's Innovation Division in 2018, where he has been involved in setting up financing and investment operations for start-ups for 5 years.

Yves GUIOL

NCI
Learn more
A graduate of École Polytechnique with a Master's degree in Innovation Management, Yves had a dual career in operational management (running a clinic and a production line) and strategy consulting in an international firm, before joining NCI in 2010 to develop an active shareholder-strategist concept by founding the Strategy Division. After several years investing in and supporting the managers of our portfolios, he took over as head of innovation capital, structuring a global acceleration scheme for startups and launching WaterStart Capital in early 2018.

Chao (Alex) HE

MICROPORT
Learn more
Pr. Chao He (Alex) is general manager of Medbot, a MicroPort’s robotics subsidiary. Founded in 1998 in Shanghai (China) with the common belief that advancements in medical technology can transform patients’ lives, MicroPort is a global leading developer, manufacturer and operator focusing on minimally invasive intervention products for the treatment of vascular diseases and pathological changes. Over the last two decades, MicroPort has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping lives and today provides over 300 devices and technologies, currently approved for use in nearly 10,000 hospitals worldwide. At MicroPort innovation is part of our DNA¸ not only in the treatments and services we develop but also in the way we foster innovation. With a vast global footprint of R&D and manufacturing sites (Shanghai; Memphis (TN) in the United States; Clamart in France; Saluggia in Italy; Santo Domingo in Dominican Republic), a strong focus on technology innovation with over 4,000 patent applications, and a global workforce of over 7,000 employees, MicroPort is committed to its vision of building a People Centric Consortium of companies focused on Emerging Medical Technologies.

Chantal Le Chat

Independent Member
Learn more
Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRays tubes as well as the Vascular organization based in Buc (France) or Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming in 2002 the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence and profitable growth. In 2005, Chantal was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation as well as introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-14, she expanded her role to cover also the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the “Ecole Supérieure de Physique et Chimie Industrielles” (ESPCI) and a Master in Medical Instrumentations, Paris France – 1985.

Medical Advisory Board

Doctor J. FAJADET

Co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress
Learn more
• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.

Professor E. DURAND

Rouen University Hospital (France)
Learn more

Professor M. HAUDE

Neuss Clinic (Germany)
Learn more
Pr. Haude has been head physician of the Medical Clinic I at the Clinic Neuss for 13 years and is thus also in charge of cardiology and of their cardiac catheter labs. In addition, Professor Haude has been involved in interventional cardiology for 31 years and has been past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology , PCR and ESC board member and EAPCI president from 2016 to 2018. He currently is an EAPCI board member, Pr. Haude has published more than 300 scientific articles.

Doctor M. NEJJARI

Centre Cardiologique du Nord (France)
Learn more
Interventional cardiologist at the Centre Cardiologique du Nord since 2014, Dr. Nejjari is an active player in new technologies and innovation in the cardiology sector.

Awards

Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015
Nominee for "Trophée de l'Avenir" 2018
by Europe 1
Nominee for French Start-up of the year 2018
by EY

Partners